Results 21 to 30 of about 19,748 (246)

Outcome of adjuvant chemotherapy with lomustine, vinblastine and chlorambucil on management of canine mast cell tumour of high to intermediate risk [PDF]

Arquivo Brasileiro de Medicina Veterinária e Zootecnia, 2017
In spite of the many available protocols, the use of chemotherapy for the management of canine mast cell tumours (MCT) remains empirical, and there is lack of criteria for the choice of protocol and definition of patients who may benefit from treatment ...
R.S. Horta, G.E. Lavalle, M.P. Costa, L.L. Moura, A. Marcinowska, R.B. Araújo   +5 more
doaj   +2 more sources

Novel therapeutic strategy targeting STMN1 using chlorambucil-conjugated pyrrole-imidazole polyamide in small cell lung cancer. [PDF]

Int J Cancer
What's New? Small cell lung cancer (SCLC) is aggressive and difficult to treat but exhibits high levels of stathmin 1 (STMN1), a candidate therapeutic target. In this study, the authors synthesized a chlorambucil (Chb)‐conjugated pyrrole–imidazole polyamide (PIP) compound targeting the STMN1 promoter and DNA sequences and evaluated its efficacy in ...
Yoshikawa R, Watanabe T, Ohtaki Y, Bando T, Sugiyama H, Araki T, Yashima H, Erkhem-Ochir B, Okami H, Dorjkhorloo G, Shioi I, Nagashima T, Kawatani N, Yazawa T, Narusawa E, Kosaka T, Kawashima O, Kamiyoshihara M, Minna JD, Girard L, Shirabe K, Nagase H, Shimizu K, Yokobori T.   +23 more
europepmc   +2 more sources

Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapyinduced leukemia [PDF]

, 2001
Glutathione S-transferases (GSTs) detoxify potentially mutagenic and toxic DNA-reactive electrophiles, including metabolites of several chemotherapeutic agents, some of which are suspected human carcinogens.
Allan, J.M., Wild, C.P., Rollinson, S., Willett, E.V., Moorman, A.V., Dovey, G.J., Roddam, P.L., Roman, E., Cartwright, R.A., Morgan, G.J.   +9 more
core   +7 more sources

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. [PDF]

, 2019
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or ...
Bairey, Osnat, Barr, Paul M., Burger, Jan A., Coutre, Steven E., Dai, Sandra, Dean, James P., Devereux, Stephen, Ghia, P, Grosicki, Sebastian, Hillmen, Peter, Kipps, Thomas J., Lal, Indu, McCarthy, Helen, Moreno, Carol, Offner, Fritz, Owen, Carolyn, Robak, Tadeusz, Simpson, David, Tedeschi, Alessandra, Universitat Autònoma de Barcelona   +19 more
core   +3 more sources

Targeting Wnt/β-Catenin Pathway by DNA Alkylating Pyrrole-Imidazole Polyamide in Colon Cancer. [PDF]

Cancer Sci
Wnt/β‐catenin pathway is aberrantly activated in various cancers. We have synthesized a novel DNA alkylating PI polyamide (WNT‐Chb) to target the consensus TCF/LEF‐responsible element. WNT‐Chb downregulated the Wnt‐target genes by inhibiting the recruitment of the β‐catenin/TCF transcription complex and reduced tumor growth in a mouse xenograft tumor ...
Shimozato O, Akao N, Yanagisawa Y, Mori Y, Zhang X, Kida Y, Igarashi R, Watanabe T, Ozaki T, Takatori A.   +9 more
europepmc   +2 more sources

Unanticipated differences between α- and γ-diaminobutyric acid-linked hairpin polyamide-alkylator conjugates [PDF]

, 2006
Hairpin polyamide–chlorambucil conjugates containing an {alpha}-diaminobutyric acid ({alpha}-DABA) turn moiety are compared to their constitutional isomers containing the well-characterized {gamma}-DABA turn.
Chou, C. James, Dervan, Peter B., Farkas, Michelle E., Gottesfeld, Joel M., Tsai, Sherry M.   +4 more
core   +4 more sources

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

Haematologica, 2018
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia.
Anne-Sophie Michallet, Melih Aktan, Wolfgang Hiddemann, Osman Ilhan, Peter Johansson, Kamel Laribi, Balkis Meddeb, Carol Moreno, João Raposo, Anna Schuh, Ali Ünal, Tom Widenius, Alf Bernhardt, Kerstin Kellershohn, Dimitri Messeri, Stuart Osborne, Véronique Leblond   +16 more
doaj   +1 more source

The curative effect of Cymbopogon citrates volatile oil against chlorambucil drug toxicity [PDF]

Journal of Bioscience and Applied Research, 2019
Chlorambucil (CLB) is a bifunctional alkylating drug widely used as an anticancer agent and immunosuppressant. CLB mutagenicity, teratogenicity, and carcinogenicity are indicated based on their structure and clinical history.
Zakaria Teleb, Kamilia Taha, Sobhy Hassab El-Nabi, Islam El-Garawani, Gouda Dawoud, Samraa El-Shafey, Hanaa El-Esawy   +6 more
doaj   +1 more source

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer

Frontiers in Pharmacology, 2023
Introduction: Development of Poly (ADP-ribose) polymerase (PARP) inhibitors has been extensively studied in cancer treatment. Olaparib, the first approved PARP inhibitor, showed potency in the inhibition of both BRCA (breast cancer associated)-mutated ...
Hongyu Qin, Jian Zhang, Yilu Zhao, Lihui Zhang, Jinhong Feng, Lei Zhang   +5 more
doaj   +1 more source

Pilot trial of fk 506 in the management of steroid-resistant nephrotic syndrome [PDF]

, 1993
Seven patients with steroid-resistant nephrotic syndrome were treated with FK 506 monotherapy. Four patients were children with focal sclerosing glomerulonephritis (FSGS).
Ellis, D, Igdal, H, McCalley, J, Shapiro, R, Shapiro, R, Starzl, TE, Starzl, TE, Starzl, TE, Tzakis, A, Tzakis, A   +9 more
core   +1 more source